The Serum M2BPGi Level Can be Practical Test to Diagnose Liver Fibrosis amongOverweight and Obese Patients in Mongolia

Э. Уранбайгаль; Д. Даваалхам; Р. Отгонбаяр

Э. Уранбайгаль Mongolian National University of Medical Sciences
Д. Даваалхам Mongolian National University of Medical Sciences
Р. Отгонбаяр Mongolian National University of Medical Sciences

Abstract

Aim: To diagnose liver fibrosis among overweight and obese population of 40-65 years in Mongolia by serum M2BPGiglyco-biomarker level.Methods. We enrolled 3315 people aged 40-65 years old who live in urban and rural areas. Questionnaires were obtainedfrom participants, and anthropometric measurements, ultrasound, and laboratory tests were done. Serum M2BPGi levelwas directly measured with the chemilumines centenzyme immune method using an automatic immunoanalyzer. Statisticalanalysis was performed on SPSS ver. 20.0; SPSS Inc., Chicago, IL software. We used Pearson chi squaretest to estimate differencebetween parameters with percentage, and T test was used to estimate median difference. Ap value less than 0.05consideredstatistically significant.Results. 3315 people participated in this study. 1955 people were recruited from Ulaanbaatar (59.0%) 1360 people werefrom rural areas, and 1141 (34.4%) were male and 2174 were female (65.6%). 1326 (40%) of the surveyed were overweightand 1038 (31.3%) were obese. Elevation of serum M2BPGI glyco-biomarker was significantly different from body weight,age group and sex (p<0.0001).Conclusion. From total participants, 40% were overweight and 31.3% were obese. The liver fibrosis was found in 51.2%of obese and overweight patient.

References

1. Abe M., Miyake T., Kuno A., et al. Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease // J. Gastroenterol. 2015. Vol. 50. №7. P.776-
2. Athyros V.G., Tziomalos K., Katsiki N., et al. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update // World J Gastroenterol. 2015. Vol. 21. P.6820-6834.
3. Baatarkhuu O., Gerelchimeg T., Munkh-Orshikh D., et al. Epidemiology, Genotype Distribution, Prognosis, Control, and Management of Viral Hepatitis B, C, D, and Hepatocellular Carcinoma in Mongolia // Euroasian Journal of Hepato- Gastroenterology. 2018. Vol. 8. №1. P.57-62. DOI: 10.5005/jpjournals-10018-1260.
4. Baatarkhuu O., Kim D.Y., Ahn S.H., et al. Prevalence and genotype distribution of hepatitis C virus among apparently healthy individuals in Mongolia: a population-based nationwide study // Liver Int. 2008. Vol. 28. №10. P.1389-1395.
5. Baatarkhuu O., Kim D.Y., Bat-Ireedui P., Han K.H. Current situation of hepatocellular carcinoma in Mongolia // Oncology. 2011. Vol. 81. Suppl. 1. P.148-151.
6. Baatarkhuu O., Kim D.Y., Nymadawa P., et al. Clinical features and prognosis of hepatocellular carcinoma in Mongolia: a multicentre study // Hepatol Int. 2012. Vol. 6. №4. P.763-769.
7. Chalasani N., Younossi Z., Lavine J.E., et al; American Gastroenterological Association; American Association for the Study of Liver Diseases; American College of Gastroenterologyh. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology // Gastroenterology. 2012. Vol. 142. P.1592-1609.
8. Dunn W., Xu R., Wingard D.L., et al. Suspected Nonalcoholic Fatty Liver Disease and Mortality Risk in a Population Based Cohort Study // American Journal of Gastroenterology. 2008. Vol. №9. P.2263-2271. DOI: 10.1111/j.1572-0241.2008.02034.x.
9. European association for the Study of the Liver, European Association for the Study of Diabetes. European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease // J Hepatol. 2016. Vol. 64. P.1388-1402. DOI: 10.1016/j. jhep.2015.11.004.
10. Hanai T., Shiraki M., Ohnishi S., et al. Impact of serum glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein levels on liver functional reserves and mortality in patients with liver cirrhosis // Hepatol. Res. 2015. Vol. 45. №11. P.1083-1090. DOI: 10.1111/hepr.12473.
11. Hannah W.N. Jr., Harrison S.A. Nonalcoholic fatty liver disease and elastography: Incremental advances but work still to be done // Hepatology. 2016. Vol. 63. P.1762-1764.
12. Harrison S.A., Torgerson S., Hayashi P.H. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study // Am J Gastroenterol. 2003. Vol. 98. P.2042-2047.
13. Hsu S.J., Enkhzaya S., Lin Y.Y., et al. Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients. // J Formos Med Assoc. 2019. pii: S0929-6646(19)30819-8. DOI: 10.1016/j.jfma.2019.10.003.
14. Idowu M.O., Chhatrala R., Siddiqui M.B., et al. De novo hepatic steatosis drives atherogenic risk in liver transplantation recipients // Liver Transpl. 2015. Vol. 21. P.1395-1402.
15. Kuno A., Ikehara Y., Tanaka Y., et al. A serum ‘sweetdoughnut’ protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis // Sci Rep. 2013. Vol. 3. P.1065.
16. Kuno A., Kato Y., Matsuda A., et al. Focused differential glycan analysis with the platform antibody-assisted lectin profiling for glycan-related biomarker verification // Mol Cell Proteomics. 2009. Vol. 8. №1. P.99-108.
17. LeoniS., TovoliF., NapoliL., et al. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis // World J Gastroenterol. 2018. Vol. 24. №30. P.3361-3373.
18. Lonardo A., Byrne C.D., Caldwell S.H., et al. GlobalEpidemiology: Non alcoholic Fatty Liver Disease: Incidence and Prevalence // Hepatology. 2016. Vol. 64. №1. P.73-84.
19. McPherson S., Hardy T., Henderson E., et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management // J Hepatol. 2015. Vol. 62. P.1148-1155.
20. Rinella M.E. Nonalcoholic fatty liver disease: a systematic review // JAMA. 2015. Vol. 313. P.2263-2273.
21. Sorrentino P., Tarantino G., Conca P., et al. Silent nonalcoholic fatty liver disease-a clinical-histological study // J Hepatol. 2004. Vol. 41. P.751-757.
22. Toshima T., Shirabe K., Ikegami T., et al. A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-binding protein (WFA(+)-M2BP), for assessing liver fibrosis // J Gastroenterol. 2015. Vol. 50. №1. P.76-84. DOI:10.1007/s00535- 014-0946-y.
23. Toshima T., Shirabe K., Takeishi K., et al. New method for assessing liver fibrosisbased on acoustic radiation force impulse:a special reference to the difference between right and left liver // J Gastroenterol. 2011. Vol. 46. №5. P.705-711.
24. Uugantsetseg G., Kim Do.Y., Tserendagva D., et al. Treatment result of peginterferon and ribavirin for chronic viral hepatitis C // Sibirskij Medicinskij Zurnal (Irkutsk). 2016. №8. P.19-22. (in Russian)
25. White D.L., Kanwal F., El-Serag H.B. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review // Clin. Gastroenterol. Hepatol. 2012. Vol. 10. P.1342-1359.e2. DOI: 10.1016/j.cgh.2012.10.001.
26. Williams C.D., Stengel J., Asike M.I., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and Сибирский медицинский журнал (Иркутск), 2019, № 4 liver biopsy: a prospective study // Gastroenterology. 2011. Vol. 140. P.124-131.
27. Wong V.W., Wong G.L., Choi P.C., et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years // Gut. 2010. Vol. 59. P.969-974.
28. Yamasaki K., Tateyama M., Abiru S., et al. Elevated serum levels of Wisteria floribundaagglutinin-positive human Mac-2 bindingprotein predict the development of hepatocellular carcinoma in hepatitis Cpatients // Hepatology. 2014. Vol. 60. №5. P.1563-1570.
29. Younossi Z.M., Koenig A.B., Abdelatif D., et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes // Hepatology. 2016. Vol. 64. P.73-84.